Key result
Rivaroxaban is noninferior to warfarin, reducing stroke or systemic embolism by ~21%.
Why the study?
Does rivaroxaban prevent stroke or systemic embolism compared to warfarin in patients with nonvalvular atrial fibrillation?
RCT (n=14,264)
Double-blind
Central computerized randomization
Yes
Does rivaroxaban prevent stroke or systemic embolism compared to warfarin in patients with nonvalvular atrial fibrillation?
Rivaroxaban is a noninferior alternative to warfarin for stroke prevention in nonvalvular atrial fibrillation, offering a lower risk of intracranial and fatal bleeding.
Answers are grounded in this paper and cite their sources.
Supports rivaroxaban as first-line option in nonvalvular AF; reinforces consensus for direct oral anticoagulants over warfarin.
In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism. There was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivaroxaban group. (Funded by Johnson & Johnson and Bayer; ROCKET AF ClinicalTrials.gov number, NCT00403767.).
No takes yet. Share an insight, caveat, or question.
Patel et al. (2011) conducted an RCT in Nonvalvular atrial fibrillation (n=14,264). Rivaroxaban vs. Warfarin (dose-adjusted) was evaluated on Composite of stroke (ischemic or hemorrhagic) and systemic embolism (HR 0.79, 95% CI 0.66-0.96, p=<0.001). Rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism, with a.79.
Synapse has enriched 10 related papers. Consider them for comparative context: